Oscar Health is trading up 8.85% on June 8, 2026, after reaffirming full-year 2026 guidance of $18.7B-$19B in Revenue at the Goldman Sachs Healthcare Conference, with utilisation trends tracking favourably, a $130 million Wakely report tailwind, and institutional buyers including BIT Capital GmbH raising their OSCR stake by 545%.

Key Highlights

  • Oscar Health reaffirmed full-year 2026 guidance of approximately $18.7B-$19B in revenue at the Goldman Sachs 47th Annual Global Healthcare Conference, reassuring investors after a volatile year shaped by ACA Subsidy uncertainty.
  • The final 2025 Wakely report came in $130 million favourable to accruals, utilisation through May remained modestly ahead of expectations, and early 2026 market morbidity data suggests lighter-than-expected claims.
  • Institutional buying added to the session momentum, with BIT Capital GmbH increasing its OSCR stake by 545% and WINTON GROUP initiating a new position in Q4.

Conference Reaffirmation Anchors the Session

Oscar Health, Inc. (NYSE: OSCR) was trading at $26.68, up 8.85% against a previous close of $24.51, touching a 52-week high of $27.20 during the session. Oscar Health is a New York City-based healthcare technology company founded in 2012 by Joshua Kushner, Kevin Nazemi, and Mario Schlosser, offering Individual and Family, Small Group, and Medicare Advantage Health Insurance plans primarily through ACA exchanges, alongside its proprietary +Oscar technology platform licensing full-stack digital infrastructure to providers and payors. With approximately 2,400 employees and a Market Capitalisation of $6.92 billion, Oscar is led by CEO Mark Thomas Bertolini. The company achieved profitability in fiscal year 2024 with $9.2 billion in total revenue, up 56.5% year-over-year.

The primary catalyst is the full-year 2026 guidance reaffirmation at the Goldman Sachs 47th Annual Global Healthcare Conference. Management confirmed projected revenue of $18.7B-$19B for FY2026, addressing investor concern about the impact of enhanced ACA subsidy expiration. Membership ended open enrollment at 3.4 million, declining to approximately 3 million in Q2 as planned.

Favourable Utilisation and Wakely Tailwind

Utilisation through May remained modestly favourable to expectations. The final 2025 Wakely report came in $130 million favourable to accruals, providing a material quarterly tailwind. Early 2026 market morbidity data also suggests lighter-than-expected claims, potentially offering further upside to the guidance range.

Institutional Buying Adds Momentum

BIT Capital GmbH increased its OSCR stake by 545% and WINTON GROUP initiated a new position in Q4, adding Demand-side momentum. The company's AI-driven programme integrity approach, detecting anomalous patterns with proactive CMS reporting, supports a clean risk pool and predictable utilisation.

Valuation and Risk Considerations

OSCR reports a trailing EPS of -$0.54 and trades without a conventional P/E ratio. The 52-week range of $10.69 to $27.20, with the session touching the top of that range, reflects both the recovery from subsidy uncertainty earlier in the year and the risk of near-term consolidation at highs. Key risks include the pace of 2027 regulatory changes, ongoing risk adjustment complexity, and the potential for market morbidity to exceed current favourable signals as the year progresses.

Conclusion

Oscar Health's 8.85% advance reflects a convergence of guidance confirmation, favourable actuarial data, and institutional repositioning. The company's profitability milestone in 2024 and the improving cost trend signals in 2026 provide a more substantive foundation for the rally than thematic sentiment alone.